OncoDaily Pulse

Aug 20, 2025, 09:39

David Braun: Meet the Experts of VIRO 2025

The Global Voices in Renal Oncology (VIRO) Virtual Congress, organized by OncoDaily, will be held on September 11–12, 2025. Chaired by Dr. Rana R. McKay with co-chair Dr. Yüksel Ürün, this year’s program will feature around 50 leading experts in renal oncology from across the globe, sharing cutting-edge updates and future perspectives.

The congress is free to attend.
Register here: https://forms.gle/qcQyaGMQfHDhanfD9

Co-Chair of VIRO

Images

Name

Rana McKay

Professor of Medicine and Urology at UC San Diego Health Co-leader of the GU Oncology Program at Moores Cancer Center

As Co-Chair of VIRO, Dr. Rana McKay (University of California, San Diego) opened the congress with her talk on
“Future Directions: Emerging Agents and Combinations.”

She emphasized the momentum in renal cell carcinoma (RCC) research, highlighting how novel immunotherapies, targeted drugs, and rational combination strategies are reshaping patient care. Dr. McKay underscored the importance of personalized, biomarker-driven approaches and global collaboration, aiming to optimize survival and quality of life worldwide.

Spotlight on Dr. David Braun

Dr. David Braun is an Assistant Professor of Medicine at Yale School of Medicine, where he specializes in medical oncology with a focus on kidney cancer research and treatment. Based in the United States, Dr. Braun is widely recognized for his work on tumor-immune interactions and the development of biomarker-driven approaches to improve outcomes for patients with renal cell carcinoma (RCC).

At the Global Voices in Renal Oncology (VIRO) Virtual Congress 2025, Dr. Braun presented on the evaluation of biomarkers in the frontline setting. He emphasized the critical role of biomarkers in guiding treatment decisions, particularly as the frontline landscape in RCC now includes multiple immunotherapy and targeted therapy combinations.

Dr. Braun highlighted how predictive biomarkers could help tailor therapy selection, ensuring that patients receive the most effective and least toxic options. He also discussed the importance of integrating biomarker research into clinical trials and fostering global collaboration to accelerate discoveries and their clinical application.